Previous 10 | Next 10 |
Zymeworks (NYSE:ZYME) rose 2% in after hours trading after investment firm All Blue Falcons raised its stake in the oncology oncology maker after its $10.50/share offer was rejected last Friday. All Blue Falcons boosted its stake to 6.9% and now owns just under 4m shares a...
Zymeworks (NYSE:ZYME) ticked down 0.6% after its board rejected a $10.50/share unsolicited proposal from investment firm All Blue Falcons and doesn't plan to enter talks with the investor. Zymeworks (ZYME) said the offer "substantially undervalues" the company and is not in the best inte...
Opportunistic proposal from activist shareholder substantially undervalues Zymeworks and is not in the best interests of shareholders Shareholders are right to question the motive behind an activist proposal that was concurrently released to the media and sent to t...
ALL BLUE CAPITAL EXPANDS ITS LEADERSHIP TEAM TO SUPPORT PROPOSED ACQUISITION OF ZYMEWORKS INC. PR Newswire Siddhartha Mukherjee, MD, Hematology and Oncology Medical Expert, Rhodes Scholar and Pulitzer Prize Winning Author, Recently Joined All Blue as Medical Advisor ...
Zymeworks shares have fallen, but the pipeline remains intact. Moreover, a special situation is brewing. Positive expectation with ZYME. For further details see: Zymeworks And The Blue Falcon Elucidation
Zymeworks Inc. (ZYME) Q1 2022 Results Conference Call May 04, 2022 04:30 PM ET Company Participants Jack Spinks - Associate Director of Investor Relations Neil Klompas - Chief Operating Officer Kenneth Galbraith - Chair and CEO Chris Astle - SVP and CFO Neil Josephson - CMO Conference Call Pa...
Zymeworks press release (NYSE:ZYME): Q1 GAAP EPS of -$1.19 misses by $0.33. As of March 31, 2022, Zymeworks had $300.5 million in cash resources consisting of cash, cash equivalents and short-term investments. For further details see: Zymeworks GAAP EPS of -$1.19 misses by $0.33
Last patient enrolled ahead of expectations in pivotal trial evaluating zanidatamab as monotherapy in 2L biliary tract cancers (BTC) Two zanidatamab data presentations at ASCO in June: 1L breast cancer and 1L gastroesophageal adenocarcinoma (GEA) Presented to...
Zymeworks (NYSE:ZYME) is scheduled to announce Q1 earnings results on Wednesday, May 4th, after market close. The consensus EPS Estimate is -$0.76 (+24.0% Y/Y) and the consensus Revenue Estimate is $3.28M (vs. $0.64M in Q121). Over the last 2 years, ZYME has beaten EPS estimates 63% of the ti...
The investment firm All Blue Capital announced on Tuesday that Alan Barge, former head of Oncology at AstraZeneca (AZN), has agreed to advise the company in its recent proposal to acquire clinical-stage biotech, Zymeworks (NYSE:ZYME). As Oncology Drug Development Advisor, Dr. Barge will ...
News, Short Squeeze, Breakout and More Instantly...
VANCOUVER, British Columbia, July 22, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that the Un...
VANCOUVER, British Columbia, July 11, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that manage...
VANCOUVER, British Columbia, June 17, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that the Un...